A diarylamine derived from anthranilic acid inhibits ZIKV replication.

Suely Silva1,2, Jacqueline Farinha Shimizu1,2, Débora Moraes de Oliveira1

  • 1Laboratory of Virology, Institute of Biomedical Science, ICBIM, Federal University of Uberlandia, Uberlândia, MG, Brazil.

Scientific Reports
|November 29, 2019
PubMed
Summary

A novel diarylamine compound (FAM E3) shows significant antiviral activity against Zika virus (ZIKV), reducing viral replication. This compound targets the ZIKV NS3 helicase, offering a potential new therapeutic avenue.